Results 91 to 100 of about 33,833 (238)

Diagnosis and management of drug-resistant tuberculosis in South African adults [PDF]

, 2014
Detection of drug-resistant tuberculosis (DR-TB) increases each year in South Africa (SA). Most cases result from airborne transmission of already resistant TB strains.
Hughes, J, Osman, M
core   +3 more sources

Activity Profiling of Nitro‐Substituted Di(Hetero)Aryl 1,3,4‐ and 1,2,4‐Oxadiazoles: Antimicrobial, Cholinesterase Inhibition and Antioxidant Potential

Archiv der Pharmazie, Volume 359, Issue 1, January 2026.
Novel nitro‐substituted diaryl 1,3,4‐ and 1,2,4‐oxadiazoles were synthesised via molecular hybridisation of bioactive heterocycles. Selected derivatives exhibited potent antimicrobial activity, including against Mycobacterium tuberculosis and Staphylococcus aureus, and cholinesterase inhibitory activity, with promising selectivity.
Enikő Šikorová, Šárka Štěpánková, Eva Frýbová, Klára Konečná, Jana Korbielová, Markéta Švarcová, Ondřej Janďourek, Václav Pflégr, Szilvia Bősze, Martin Krátký   +9 more
wiley   +1 more source

A mitochondrial based oncology platform for targeting cancer stem cells (CSCs) : MITO-ONC-RX [PDF]

, 2018
Here, we wish to propose a new systematic approach to cancer therapy, based on the targeting of mitochondrial metabolism, especially in cancer stem cells (CSCs).
Bela Ozsvari, Ernestina Marianna De Francesco, Federica Sotgia, Gloria Bonuccelli, Marco Fiorillo, Martin W, Michael P. Lisanti, Sotgia F   +7 more
core   +2 more sources

Anti‐Tubercular Drug‐Induced Liver Injury: Current Understanding and Emerging Directions

JGH Open, Volume 10, Issue 1, January 2026.
ABSTRACT Most common adverse effect causing cessation of anti‐tubercular treatment (ATT) is drug‐induced liver injury (DILI) which is unpredictable due to its idiosyncratic nature. ATT is the most common cause of DILI and drug‐induced acute liver failure (ALF) in South East Asia.
Shubham Prasad, Himanshu Narang, Saurabh Kedia, Vineet Ahuja   +3 more
wiley   +1 more source

Inhalable Dry Powder of Bedaquiline for Pulmonary Tuberculosis: In Vitro Physicochemical Characterization, Antimicrobial Activity and Safety Studies

Pharmaceutics, 2019
Bedaquiline is a newly developed anti-tuberculosis drug, conditionally approved by the United States Food and Drug Administration (USFDA) for treating drug-resistant tuberculosis in adults.
Mohammad A. M. Momin, Bhamini Rangnekar, Shubhra Sinha, Chen-Yi Cheung, Gregory M. Cook, Shyamal C. Das   +5 more
doaj   +1 more source

The multivariate analysis of results of bedaquiline use in the therapy of MDR/XDR pulmonary tuberculosis

Туберкулез и болезни лёгких, 2020
The objective of the study: to perform the multivariate analysis of treatment outcomes in patients with multiple/extensive drug resistant tuberculosis (MDR/XDR TB), including those with HIV infection, whose chemotherapy regimens included bedaquiline ...
N. V. Stavitskaya, I. G. Felker, E. M. Zhukova, А. I. Tlif, N. P. Doktorova, D. А. Kudlay   +5 more
doaj   +1 more source

Assessing the safety of bedaquiline: insight from adverse event reporting system analysis

Frontiers in Pharmacology
Background The development and marketing of Bedaquiline (BDQ) represent significant advancements in treating tuberculosis, particularly multidrug-resistant forms. However, comprehensive research into BDQ’s real-world safety remains limited.
Jiaqiang Wu, H. Pan, Li Shen, Mingyi Zhao   +3 more
semanticscholar   +1 more source

Challenges and recent progress in drug discovery for tropical diseases [PDF]

, 2018
Infectious tropical diseases have a huge effect in terms of mortality and morbidity, and impose a heavy economic burden on affected countries. These diseases predominantly affect the world’s poorest people.
A Guidi, A Hoerauf, AF Francisco, AK Kakkar, AK Njamnshi, AN Cowell, B Amadi, B Baragana, B Blasco, B Wahid, Beatriz Baragaña, CA Fux, CD Huston, CE Barry III, CE Coltart, D Sissoko, DA Lamprecht, DG Brown, DI Stanisic, DM Plouffe, DS Shepard, DT Hoagland, E Bushell, E Chatelain, E Chatelain, E Check Hayden, E Tacconelli, E Torreele, E Wit de, F Josephson, F Macintyre, FJ Sanchez-Valdez, FX Blanc, G Priotto, G-Finder, H Myllymaki, Hotez, I Angulo-Barturen, I Kramnik, I Molina, Ian H. Gilbert, ID Olaru, IPFMA, J Keiser, J Liu, J Whitehorn, JG Kublin, JN Burrows, JP Sarathy, JR Perfect, JS McCarthy, JS McCarthy, K Awadzi, K Basile, KH Mayer, KK Irwin, KL Kotloff, L Conteh, LJ Zhan, LL Silver, M Lee, M Matsumoto, MA Hulverson, Manu De Rycker, MB Jimenez-Diaz, MC Field, MC Pawlowic, MF Fromm, ML Ang, ML Hovlid, MS Love, MY Lim, N Ford, N Gyawali, N Lander, N Woodford, NA Meanwell, NJ White, NJ White, NJ White, NR Mansour, OP Singh, P Buscher, P Horvath, P Steinmann, PG Wyatt, PJ Hotez, R Rajasingham, R Taylor, RT Jacobs, S Baker, S Brooker, S Khare, S Sayasone, SA Mikolajczak, SD Pion, SH Xiao, SM Hammer, Suzanne L. Duce, T Paquet, TF Koning-Ward de, TK Warren, TN Wells, U Klarmann-Schulz, UH Manjunatha, UH Manjunatha, V Boldescu, V Mesu, VK Wong, W Checkley, W Moser, W Moser, W Zheng, Warren, World Health Organization, X Li, Y Debing, Y Wang   +117 more
core   +2 more sources

Extensive Lymphadenopathy in an HIV‐Negative Patient With Multidrug‐Resistant Tuberculosis

Respirology Case Reports, Volume 14, Issue 1, January 2026.
Extensive lymphadenopathy is uncommon in HIV‐negative patients with tuberculosis. This clinical image highlights the striking CT appearance of extensive extrapulmonary lymph node involvement in symptomatic multidrug‐resistant tuberculosis, even in the absence of HIV infection. ABSTRACT Tuberculous lymphadenitis is generally more severe in patients with
Tomoyuki Araya, Toshiyuki Kita, Kazuhiko Iwasaki, Takayuki Higashi, Ryo Hara, Hazuki Takato   +5 more
wiley   +1 more source

Predictions of Bedaquiline Central Nervous System Exposure in Patients with Tuberculosis Meningitis Using Physiologically based Pharmacokinetic Modeling

Clinical Pharmacokinetics
The use of bedaquiline as a treatment option for drug-resistant tuberculosis meningitis (TBM) is of interest to address the increased prevalence of resistance to first-line antibiotics.
Krina Mehta, Pavel Balazki, P. van der Graaf, Tingjie Guo, J. G. V. van Hasselt   +4 more
semanticscholar   +1 more source